Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Zosano's M207 shows treatment effect in late-stage migraine study; shares ahead 19%

Published 09/13/2017, 11:52 AM
© Reuters. Zosano's M207 shows treatment effect in late-stage migraine study; shares ahead 19%
ZSANQ
-
  • Zosano Pharma (ZSAN +19%) perks up, albeit on light volume, on the heels of a presentation of results from the Phase 2/3 ZOTRIP study assessing lead product candidate M207 for the acute treatment of migraine. The data were presented a the International Headache Society Congress in Vancouver.
  • As previously reported, the study met both primary endpoints. 41.5% of patients receiving the 3.8 mg dose of M207 were pain-free at two hours post dose while 31.7% were pain-free 2 - 24 hours post dose and 26.8% pain-free 2 - 48 hours post dose.
  • M207 is a zolmitriptan-coated microneedle patch is that is designed to rapidly deliver zolmitriptan during a migraine attack. Zolmitriptan was marketed as a branded medicine by AstraZeneca before coming off patent several years ago. Its development is ongoing.
  • Previously: Zosano's lead product candidate successful in late-stage migraine study; shares ahead 46% premarket (Feb. 13)
  • Now read: Ablynx - Catalyst Next Month, Good Midterm Buy


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.